Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

BACKGROUND Loss of HER2 "positivity" can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2-positivity loss after neoadjuvant dual HER2-targeted treatment plus chemotherapy, the current standard-of-care for most early stage HER2-positive breast cancers, is not well described. Previous studies that report the HER2 discordance rate after neoadjuvant treatment also do not include the novel HER2-low category. In this retrospective study, we determine the incidence and prognostic impact of HER2-positivity loss, including the evolution to HER2-low disease, after neoadjuvant dual HER2-targeted therapy with chemotherapy. METHODS Clinicopathologic data for patients with stage I-III HER2+ breast cancer diagnosed between 2015 and 2019 were reviewed in this single institution retrospective study. Patients who received dual HER2-targeted treatment with chemotherapy were included, and HER2 status before and after neoadjuvant therapy was interrogated. RESULTS A total of 163 female patients were included in the analysis with a median age of 50 years. A pathologic complete response (pCR as defined by ypT0/is) was achieved in 102 (62.5%) of 163 evaluable patients. Among the 61 patients with residual disease after neoadjuvant therapy, 36 (59.0%) had HER2-positive and 25 (41.0%) had HER2-negative residual disease. Of the 25 patients with HER2-negative residual disease, 22 (88%) of patients were classified as HER2-low. After a median follow-up of 3.3 years, patients who retained HER2-positivity after neoadjuvant treatment had a 3-year IDFS rate of 91% (95% CI, 91%-100%), while patients who lost HER2-positivity had a 3-year IDFS rate of 82% (95% CI, 67%-100%). CONCLUSION Almost half of patients with residual disease following neoadjuvant dual HER2-targeted therapy plus chemotherapy lost HER2-positivity. The loss of HER2-positivity may not confer negative prognostic impact, although the results were limited by short follow-up time. Further research on the HER2 status after neoadjuvant treatment may help guide treatment decisions in the adjuvant setting.

[1]  N. Loman,et al.  Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE , 2022, npj Breast Cancer.

[2]  M. Küçüköner,et al.  Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. , 2022, Future oncology.

[3]  G. Curigliano,et al.  Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. , 2022, Cancer discovery.

[4]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[5]  M. Fassan,et al.  HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment , 2022, npj Breast Cancer.

[6]  S. Gardiner,et al.  Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes , 2021, Journal of surgical oncology.

[7]  S. Chandarlapaty,et al.  Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer. , 2021 .

[8]  I. Ellis,et al.  Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer , 2021, Modern Pathology.

[9]  T. Ignatov,et al.  Loss of HER2 after HER2-targeted treatment , 2019, Breast cancer research and treatment.

[10]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[11]  S. André,et al.  Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. , 2019, American journal of translational research.

[12]  A. Ozet,et al.  Receptor discordances after neoadjuvant chemotherapy and their effects on survival. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[13]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[14]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[15]  Seigo Nakamura,et al.  Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer , 2017, Journal of surgical oncology.

[16]  D. Dodwell,et al.  Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. , 2016, European journal of cancer.

[17]  H. Miyata,et al.  Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Z. Shao,et al.  Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis , 2016, Breast Cancer Research and Treatment.

[19]  A. Bilici,et al.  Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer. , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[20]  A. Wolff,et al.  Treatment of HER2-positive breast cancer. , 2014, Breast.

[21]  M. Dieci,et al.  Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Eunyoung Kang,et al.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.

[23]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[24]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Hortobagyi,et al.  Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes , 2009, Clinical Cancer Research.

[26]  D. Slamon,et al.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.